Abstract: Herein is reported a method for purifying a polypeptide comprising the steps of i) applying a solution comprising the polypeptide to an ion exchange chromatography material, and ii) recovering the polypeptide with a solution comprising a denaturant and thereby purifying the polypeptide, whereby the ion exchange chromatography material comprises a matrix of cross-linked poly (styrene-divinylbenzene) to which ionic ligands have been attached, and wherein the solution comprising the polypeptide applied to the ion exchange chromatography material is free of the denaturant and the polypeptide adsorbed to the ion exchange chromatography material is recovered with a solution comprising a denaturant at a constant conductivity.

Abstract: This invention relates to the treatment of Alzheimer's disease, the reduction of the progression of Alzheimer's disease, and the alleviation of symptoms of Alzheimer's disease by administering ApoA-1 Milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an rAAV vector encoding ApoA-1 Milano or an active fragment thereof, to a mammal having Alzheimer's disease or a symptom of Alzheimer's disease.

Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Abstract: The present invention relates to monoclonal anti-HPV (human papillomavirus) E7 antibodies capable of specifically recognising an epitope of the C-terminal or the N-terminal region of a HPV E7 protein, diagnostic compositions and kits comprising said antibodies as well as methods for immunohistochemical and ELISA-based diagnosis of HPV infections utilizing said antibodies.

Abstract: The present description relates to anti-Thermus thermophilus SlyD FKBP domain antibodies and methods of using the same.

Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Abstract: The invention provides compositions and methods for preventing or reducing photoreceptor cell death. The invention further provides compositions and methods for treating, preventing, or alleviating symptoms of retinal detachment.

Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.

Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: A method of treating a disease associated with activated B lymphocytes expressing Tetraspanin 33 (TSPAN33/BAAM). The disease can be, for example, lymphoma or an immune disease. The method includes administering an anti-TSPAN33/BAAM antibody to a patient in need of such treatment in an amount effective to treat the disease. Methods of purifying activated B cells and identifying activated and/or diseased B cells are also provided.

Abstract: Disclosed herein is an antibody that binds to a voltage sensor paddle (VSP) of Nav1.7. Also disclosed herein are methods of treating pain, itch, neurogenic inflammation, or cough in a subject in need thereof. The methods include administrating the antibody to the subject.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

Abstract: Disclosed herein are immunoglobulin fusion proteins that have a first antibody region attached to an extender fusion region. The extender fusion region contains a therapeutic agent and a beta strand secondary structure. The extender fusion region may contain 7 or fewer consecutive amino acids based on or derived from an ultralong CDR3. Alternatively, the extender fusion region contains a rigid stalk protein structure, but does not contain an amino acid sequence based on or derived from an ultralong CDR3. The extender fusion region may also have one or more linkers or proteolytic cleavage sites. The immunoglobulin fusion proteins may have additional therapeutic agents and extender fusion regions. Also disclosed herein are pharmaceutical compositions of immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

Abstract: The invention provides anti-FGFR4 antibodies and methods of using the same.

Abstract: The invention relates to the invention relates to methods and compositions for targeting tumor microenvironment (TME) and for preventing metastasis. The invention also relates to methods and compositions for inhibiting the pro-invasive stromal fibroblast activity as well as the pro-invasive stromal fibroblast activation in a patient in need thereof such as a patient affected with a solid cancer.

Abstract: The present invention provides, among other things, methods and compositions for the treatment of cancer. The present invention is based, in part, on the surprising discovery that ablation of regulatory T cells (Treg), for example, transient ablation of Treg, is able to drastically reduce tumor burden and reduce metastasis when used as a single agent. In some embodiments, provided methods and compositions are used in combination with one or more other anti-tumor therapies, for example, ionizing radiation.

Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the TWEAKR (TNFRSF12A, FN14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the TWEAKR. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for us.

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

Abstract: In the field of therapy, specifically patient-specific immune therapy for cancer, improved therapeutic modalities are provided for. The identity and dosage of the administered anti-tumor antibodies is determined and dynamically adjusted to the individual patient's condition, disease and/or treatment progression, thus providing anti-cancer treatment which may be particularly advantageous for the treatment of heterogeneous tumors.

Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.

Abstract: The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.

Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Abstract: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.

Abstract: We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell-mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.

Abstract: The present invention relates to immunoglobulin new antigen receptors (IgNARs) from fish and uses thereof. In particular, the present invention relates to modified IgNAR variable domains and to domains from members of the immunoglobulin superfamily that have been modified to include structural features derived from IgNAR variable domains.

Abstract: Described are a method for processing cellulose-containing biomass and the use of methanesulfonic acid for processing cellulose-containing biomass, especially for the pretreatment of cellulose-containing biomass prior to saccharification.

Abstract: The present invention relates to a phase-stable suspension of cellulose II in water, having a high water retention capacity and a cellulose concentration between 0.1 and 5.0% by weight, a method of its preparation, and its use.

Abstract: The invention concerns a process for the manufacture of an acylated polysaccharide which comprises. (a) reacting a polysaccharide with an acylating agent to produce an acylated polysaccharide and (b) washing the acylated polysaccharide with water containing from 0.05 to 15 mg/l Ca2+-ions (c) recovering the washed acylated polysaccharide and an aqueous phase containing carboxylic acid from step (b).

Abstract: Processes disclosed are capable of converting biomass into high-crystallinity nanocellulose with low mechanical energy input. In some variations, the process includes fractionating biomass with lignosulfonic acids, to generate cellulose-rich solids; and mechanically treating the cellulose-rich solids to form nanofibrils and/or nanocrystals. The strong lignosulfonic acids created during delignification give a pH less than 1 and hydrolyze preferentially the amorphous regions of cellulose. The total mechanical energy may be less than 500 kilowatt-hours per ton. The crystallinity of the nanocellulose material may be 80% or higher, translating into good reinforcing properties for composites. The nanocellulose material may include nanofibrillated cellulose, nanocrystalline cellulose, or both. In some embodiments, the nanocellulose material is hydrophobic via deposition of lignin onto the cellulose surface.

Abstract: The present disclosure is generally directed to biopolymers having coiled nanostructures, methods of making those biopolymers, and applications involving those biopolymers. Biopolymers having coiled nanostructures may be produced through a biophysical process by which the shape of a biopolymer macromolecular chain is altered. Biopolymers having coiled nanostructures may then be cross-linked to prepare biopolymeric networks. The biopolymeric networks may be configured to incorporate solid particles, in which they serve to hold the solid particles together against external stresses, solvents, and the like. For this reason, the biopolymers having coiled nanostructures are useful in a variety of applications, including in an improved process for forming iron ore pellets.

Abstract: The invention concerns a process for the manufacture of an acylated polymer composition comprising amylose and/or amylopectin, comprising a pre-treatment step in the presence of an acid and a hydroxycarboxylic acid, subsequent acylation and, preferably, a post-treatment step with an acid. The products obtained are useful as additives in inks, varnishes, lacquers, coatings, thickeners, adhesives or binders.

Abstract: A method for producing chitosan from naturally occurring chitin-containing raw material, such as crustacean shells, includes an optional pretreatment step to remove non-chitin rich organic material for example, shrimp flesh, from the raw material, e.g., shrimp shells. The optional pre-treatment is followed by a demineralization step utilizing a mild hydrochloric acid solution and a deproteination step utilizing a mild sodium hydroxide solution. The deproteination step is followed by a deacetylation step to remove the acetyl group from N-acetylglucosamine (chitin) to form an amine group, yielding d-glucosamine (chitosan). Each step is followed by a washing step and the product is dried, preferably at a temperature not in excess of about 65° C. Known purification and grinding steps may also be used to produce the final chitosan product. The process is carried out in equipment comprising a series of substantially identical or similar tanks (18, 26, 36, etc.) and dryers (62, 62?), suitably interconnected.

Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.

Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glucosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glucosaminoglycan derivatives are obtained from natural or synthetic glucosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glucosaminoglycan by oxidation of said glucosaminoglycan.

Abstract: A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with an imine compound containing a cyano group.

Abstract: A reactor for in-line processing includes a housing coupled to a geometrically reflective structure. A plurality of radiation sources, such as LED lights, as disposed in the housing and arranged such that they project their radiation into the geometrically reflective structure. A material to be cured is to be exposed to radiation as it passes though the geometrically reflective structure.

Abstract: An oxolanyl compound-containing composition comprising specified amounts of the meso-isomer of one or more of the oxolanyl compounds of specified structure is provided. Also provided are methods for the use of such compositions as vinyl content modifiers in polymerization processes.

Abstract: The present invention relates to the treatment and recycle of effluent streams from a polymerisation process, and in particular provides a polymerisation process comprising the steps of: 1) Polymerising a monomer and a comonomer in a polymerisation reaction, 2) Withdrawing an effluent stream comprising solid polymer and a mixture comprising unreacted monomer and unreacted comonomer, and passing the effluent to a high pressure recovery system comprising a. a high pressure separation step for separating a vapour comprising unreacted monomer and unreacted comonomer from said solids, and b. a high pressure recycle system for recycling a portion of the vapour to the polymerisation reaction, 3) Passing the solids from the high pressure recovery system to a low pressure recovery system comprising a. a low pressure separation step for separating further unreacted monomer and unreacted comonomer from said solids, and b.

Abstract: Acetoacetyl group-containing polyvinyl alcohol resin powder composition containing a C1 to C3 alcohol in an amount of 0.5 to 4 wt % is produced by allowing a powdery polyvinyl alcohol resin to react with diketene, washing the resulting acetoacetyl group-containing polyvinyl alcohol resin particles with the C1 to C3 alcohol to remove an unreacted portion of the diketene, and drying the intermediate acetoacetyl group-containing polyvinyl alcohol resin particles composition at a temperature of 40° C. to 120° C. at a pressure of not higher than 20 kPa after the washing. The acetoacetyl group-containing polyvinyl alcohol resin powder composition thus produced is highly soluble in water.

Abstract: A compound represented by the following general formula (1):

Abstract: A process for the preparation of optionally asymmetric acetal compounds includes reacting a compound containing a hydroxyl group with a vinylether compound in the presence of a zwitterionic catalyst including at least one basic nitrogen containing structural fragment and at least one sulfonic acid group in its structure, with the proviso that a molar ratio of the basic nitrogen to sulfonic acid is 1:1

Abstract: A method for preparing a coupled polymer, the method comprising the steps of (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with an imide compound containing an oxiranyl group.

Abstract: The present invention relates to a hybrid supported metallocene catalyst. More specifically, the present invention relates to a hybrid supported metallocene catalyst using two or more different types or more of metallocene compounds, among which one type of the metallocene compounds shows a high polymerization activity even when it is supported, and thus the catalyst has an excellent activity and can be utilized in the polymerization of olefinic polymers having ultra-high molecular weight. Based on the hybrid supported metallocene catalyst of the present invention, an olefinic polymer having high molecular weight and the desired physical property can be prepared.

Abstract: The present invention relates to a method for preparing a hybrid supported metallocene catalyst. More specifically, the present invention relates to a method for preparing a hybrid supported metallocene catalyst by using two or more different types of metallocene compounds. One type of the metallocene compounds shows a high polymerization activity even when it is supported, and thus the catalyst has an excellent activity and can be utilized in the polymerization of olefinic polymers having ultra-high molecular weight. Based on the hybrid supported metallocene catalyst obtained according to the preparation method of the present invention, an olefinic polymer having high molecular weight and the desired physical property can be prepared.

Abstract: The present invention provides a modified polytetrafluoroethylene fine powder which can be processed into molded articles high in thermal stability, chemical resistance and transparency and for which the extrusion pressure can be lowered. The present invention is a modified polytetrafluoroethylene fine powder, wherein the cylinder extrusion pressure at a reduction ratio of 1600 is not higher than 50 MPa and the haze value of molded article a for measurement formed therefrom is not higher than 60.